Universal Beteiligungs und Servicegesellschaft mbH Reduces Holdings in Boston Scientific Corporation $BSX

Universal Beteiligungs und Servicegesellschaft mbH decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 1.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,333,127 shares of the medical equipment provider’s stock after selling 21,558 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.09% of Boston Scientific worth $130,153,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State Street Corp lifted its holdings in Boston Scientific by 1.1% in the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Synergy Asset Management LLC increased its stake in Boston Scientific by 3,493.0% during the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC lifted its stake in shares of Boston Scientific by 39.5% in the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after acquiring an additional 14,700 shares during the period. Bank Pictet & Cie Europe AG increased its position in shares of Boston Scientific by 75.3% during the 2nd quarter. Bank Pictet & Cie Europe AG now owns 164,654 shares of the medical equipment provider’s stock valued at $17,685,000 after purchasing an additional 70,753 shares during the period. Finally, Channel Wealth LLC grew its holdings in Boston Scientific by 70.8% during the third quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after acquiring an additional 11,847 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on BSX. Needham & Company LLC restated a “buy” rating on shares of Boston Scientific in a report on Thursday, January 15th. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday. Barclays boosted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Citigroup restated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, January 14th. Finally, Oppenheimer dropped their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and a consensus target price of $123.89.

Insider Buying and Selling

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 93,095 shares of company stock worth $9,305,450 in the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $91.16 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The company has a 50-day moving average of $96.42 and a 200-day moving average of $100.06. The company has a market capitalization of $135.14 billion, a price-to-earnings ratio of 48.75, a PEG ratio of 1.56 and a beta of 0.67. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.